Member Info for Bobbler

The Sun is out and all looking good at the start of a glorious day.

Hopefully good news is around the corner, what’s not to be happy about. Have a good and positive day to all GH.

Probably wise to remember they said “Anticipate q2” it wouldn’t surprise me if we have a little drift. In the grand scheme of things it’s not really a big deal if we don’t see an update for a couple of weeks.

Good morning JB, interesting find. My guess is that it’s a historical link to the original U.K. application to the MHRA. The website is completely down, so unfortunately it’s not possible to follow the link. Still a good find and worth exploring.

SOG- In this instance I think your last paragraph is a big ask, and very unlikely to happen. 😀

Subtle de-ramping, pointless waste of time.

The ramblings of someone with multiple personalities. Not sure if you could get anymore contradictory views into one post!

The observed success rates of academic drug discovery and development were 75% at phase I, 50% at phase II, 59% at phase III, and 88% at the new drug application/biologics license application (NDA/BLA) phase. These results were similar to the corresponding success rates of the pharmaceutical industry.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226120/#:~:text=The%20observed%20success%20rates%20of,(NDA%2FBLA)%20phase.

Good response 👍

Just reading a post by Criticalthinker1 over on the ADVFN board. He stated “psoriasis...which any biochemist knows is the holy grail of immuno oncology”.

I assume the majority on here, like myself, struggle to really understand the science. I have to admit I have never given a second thought to the significance of SDC1802. I’ve concentrated on the lead molecule SDC1801.

It certainly does appear there is a possible link between Psoriasis and cancer. Just imagine the potential if Sareum have deciphered the map to the holy grail.

Certainly food for thought, maybe that is why they have chosen Psoriasis as their initial target for 1801.

“Psoriasis patients collectively have a high chance of developing both generalised cancer and organ-specific cancer. The primary cause of the connection between psoriasis and cancer is still mostly unknown. ”

https://www.sciencedirect.com/science/article/abs/pii/S1567576923007877#:~:text=Psoriasis%20causes%20generalised%20and%20organ,with%20psoriasis%20and%20various%20cancers.

This trial is also being conducted in Australia by Chinese company.

https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12623000375651

Website claims:

It has completedthe Phase I clinical trial in Australia demonstrating an outstanding safety and PK/PD profile. AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases

Accro Bioscience is developing AC-201, a potent and selective oral small molecule inhibitor of tyrosine kinase 2 (TYK2) and JAK1, indicated for treatment of the moderate-to-severe plaque psoriasis.

Dosage Form:Tablet

Mode of Administration:Oral

For Part 1 (Single Ascending Dose):

A total of 40 subjects in 5 dose levels

ACTRN12623000375651

Application was submitted 8 days after Sareum's

If it spikes at £10 there will a lot of people with a serious spike in their blood pressure!

Happy to take the risk 😆👍

HBD- I assume you mean Tyk-kickers 😀

Good morning all, looks like a fine day.

Be nice to see 40p fall today 👍

And a very nice fact indeed Basil 👍

HBD ref SRA737, I think the partner could possibly be Boehringer Ingelheim US subsidiary, technically this is a private US based company, ultimately owned by the parent in Germany. Boehringer Ingelheim Inc will have issued shares (private) and could therefore offer them as part of the deal.

Boehringer Ingelheim Collaborate extensively with Cancer Research Technology (trading as Cancer Research Horizons).

Full Disclosure of interactions with industry:

Sometimes, through Cancer Research Technology Limited, Cancer Research UK will receive shares rather than financial payments when research partnerships are created. Cancer Research UK does not usually apply a market value to such shareholdings but some information concerning these shareholdings can be found in Cancer Research Technology Limited’s statutory accounts filed at Companies House.

Boehringer are significantly involved in combo trials of xentuzumab with other drugs.

https://pubmed.ncbi.nlm.nih.gov/37308971/

Researchers based at the University of Oxford have discovered a way to boost the effectiveness of a new type of drug, called xentuzumab, which is currently being tested for breast cancer.

They found that xentuzumab was most effective when combined with drugs MK-8776 and SRA737, which block a protein called CHK1, and AZD1775 that blocks WEE1 protein.

https://breastcancernow.org/about-us/research-news/researchers-discover-way-boost-effectiveness-new-breast-cancer-drug/

Potnak, I agree with your observation ref Genius. However don’t you think the shear number of posts suggests more than just someone offering their opinion?

Nicely, if someone told you a snowman was white you’d still have a contradictory view.

I agree Nicely, would have saved us all the risk of death from boredom.

Don’t say that Gregorio, I love you long time